Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tumor Infiltrating Lymphocytes in Advanced Solid Tumors
NCT05087745Phase 1Recruiting
- Sponsor
- Juncell Therapeutics
- Start
- Dec 2021
- Primary completion
- Dec 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous tumor-infiltrating lymphocytes in solid tumor, sponsored by Juncell Therapeutics. Primary endpoints: Adverse Events at 6 months, Objective Response Rate at 36 months and 4 more. Started Dec 2021; status: recruiting.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05087745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05087745.